Leo Reis MD MSc PhD MBA Fulbright UroScience

In @ScienceMagazine today Blocking a prostaglandin receptor (EP2) can keep tissue resident macrophages clearing senescent white blood cells from aged organs, slow their aging in experimental mouse model science.org/doi/10.1126/sc… science.org/doi/10.1126/sc…

🎙️ 500 episodes. Countless conversations. One incredible community. Thank you to every guest, listener, and supporter who has helped make #Uromigos a trusted voice in GU oncology. Here's to the next 500. Listen to Episode 500: Apple: podcasts.apple.com/us/podcast/epi… Spotify: open.spotify.com/episode/0i5i12… GU Oncology Now: guoncologynow.com/podcast/episod… #GUOnc #Oncology #Episode500

The internet doesn't bring out the worst in people. It makes the worst people more visible. Across all 30 countries studied, those who are nasty in online political discussions are nasty in real life, too. They seek status through hostility. Don't feed the hand that bites you.

What does tobacco harm reduction really mean? In this week's episode of The @SmokelessWord: Live from the Lab, Dr James Murphy and Dr Elaine Round, SVP of Science & Regulatory Affairs at R.J. Reynolds, get to the heart of this question. Tune in to find out more.

@TheodoreLytras @edelmann_domi @VickersBiostats It also naturally explains (in part) why different institutions, countries, and healthcare systems can obtain different outcomes despite following the same evidence.

@TheodoreLytras @edelmann_domi @VickersBiostats Gap between how things are expected to work under idealized assumptions and how they actually behave in real-world settings, where complexity, human factors, resource constraints, and unforeseen variables come into play.

When I report that I am doing a randomized trial, this is in distinction to a study with non-randomized or historical controls. But when a researcher claims to be analyzing "real world data", this is in distinction to what exactly?

@edelmann_domi @VickersBiostats Results often differ across practices due to varying levels of complexity, human factors, resource constraints, and unforeseen variables.

@edelmann_domi @VickersBiostats RCTs establish efficacy under controlled conditions. RWE evaluates how well those findings translate into a routine clinical practice by assessing their applicability, reproducibility, and representativeness. Both are essential, but they answer different questions.

🚨 ARTO long-term update in oligometastatic mCRPC: SBRT to all mets + abi/ADT vs abi/ADT alone. @TheLancetOncol 👥 157 pts 🎯 ≤3 bone/nodal mets 💊 Abiraterone + ADT ± MDT/SBRT ⏱️ Median follow-up: 53 mo Results: ✅ OS: NR vs 50 mo ✅ HR 0.55, p=0.021 ✅ bPFS: 44 vs 18 mo ✅ rPFS: 44 vs 17 mo ✅ PC-specific survival improved ✅ No major toxicity signal from adding SBRT Big signal: MDT may be more than “delay next therapy” in oligometastatic CRPC. Caveat: phase 2, unplanned OS analysis, not originally powered for OS. Still: hard to ignore. 🔥 🔗shorturl.at/rEx5L @PCFnews @PCF_Science @urotoday @renalandurology @UrologyTimes #prostatecancer

BCG+mitomycin vs BCG alone in BCG-naïve NMIBC — the ANZUP 1301 phase 3 trial (n=501) 🟰Not superior on DFS (75% vs 71% at 2 yr) 🥴 But the combination used 39% ⬇️BCG doses (median 9 vs 16) & more patients completed their planned treatment (78% vs 68%) In a 🌐of ongoing BCG shortages 🟰 outcomes with substantially less BCG is a practical win @EUplatinum @Uroweb @UrowebESU sciencedirect.com/science/articl…

@VickersBiostats A beautiful package doesn’t make the product better. When the branding is sophisticated, the evidence may be perceived as stronger than it actually is. Science has its own placebo effect: compelling terminology can never compensate for weak methodology.

@ReisLO It is used as a more scientific and rigorous sounding term than "observational data". Observational data has its strengths and its limitations and may or may not be subject to exactly the same problems as RCT evidence.

If pathology influences how we operate, shouldn't we know it before or during surgery? Renal mass biopsy remains underutilized. We explored whether AI can predict final pathology from intraoperative gross tumor images. Early results are encouraging, and we're just getting started. Led by #MilanPatel. sciencedirect.com/science/articl…

Comprehensive review on the management of localized bladder cancer in @NatRevClinOncol: from BCG-unresponsive NMIBC to perioperative immunotherapy, bladder-preserving strategies, and the emerging role of ctDNA-guided decisions in MIBC. Personalization is increasing, but careful patient selection remains key. doi.org/10.1038/s41571… #BladderCancer

@MaxKates High-priority topic …

At an FDA symposium in May, I was asked to discuss the BCG shortage which continues unabated unlike in Canada or Europe. In this editorial, we outline the paradox of approving non-tice BCG combinations while not allowing alternative strains in the market auajournals.org/doi/abs/10.109…

Cape Verde 🇨🇻 that is the tweet … ⚽️